Portal:AOP/FeaturedPathways
From WikiPathways
|
Image does not exist COVID-19 AOP (Homo sapiens) |
Image does not exist Mitochondrial Complex I inhibition leading to parkinsonian motor deficits (Homo sapiens) |
Image does not exist Mitochondrial Complex I inhibition leading to chemical induced fanconi syndrome (Homo sapiens) |
Image does not exist Adverse Outcome Pathway (AOP) for Mitochondrial Complex 1 (C1) inhibition (Homo sapiens) |
|
Image does not exist Protein alkylation leading to liver fibrosis (Homo sapiens) |
Image does not exist Lung fibrosis (Homo sapiens) |
Image does not exist Lung fibrosis (Mus musculus) |
Image does not exist Epilepsy Adverse Outcome Pathway (Homo sapiens) |
|
Image does not exist Liver steatosis AOP (Homo sapiens) |
Image does not exist Steatosis AOP (Homo sapiens) |
Image does not exist Selective serotonin reuptake inhibitors lead to several adverse outcomes (Homo sapiens) |
Image does not exist Gastric ulcer formation (Homo sapiens) |
|
Image does not exist Nanoparticle-mediated activation of receptor signaling (Homo sapiens) |
Image does not exist Nanomaterial induced apoptosis (Homo sapiens) |
Image does not exist Nanoparticle triggered regulated necrosis (Homo sapiens) |
Image does not exist Nanoparticle triggered autophagic cell death (Homo sapiens) |
|
Image does not exist Overview of nanoparticle effects (Homo sapiens) |
Image does not exist Nanomaterial induced inflammasome activation (Homo sapiens) |
Image does not exist Nanoparticle-mediated activation of receptor signaling (Bos taurus) |
List of featured pathways:
